Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period.
The aims of the present study were to assess antiplatelet drug use patterns after a first myocardial infarction (MI) and to evaluate the determinants of antiplatelet nonpersistence.



The present study was conducted in 4690 patients from the Utrecht Cardiovascular Pharmacogenetics cohort with a first MI between 1986 and 2010, who were followed for a maximum of 10 years. Medication use and event diagnosis were obtained from the Dutch PHARMO Record Linkage System. Antiplatelet drug users were classified as persistent users (gap between prescriptions ≤90 days), nonpersistent users (>90-day gap and no refills), and restarters (a new prescription after a >90-day gap). The association between potential determinants and antiplatelet nonpersistence was analysed using Cox regression.



The proportions of persistent users decreased from 84.0% at the 1-year follow-up to 32.8% at 10 years for any antiplatelet drug, and 77.3% to 27.5% for aspirin; and 39.0% to 6.4% for clopidogrel at 6 years. Most nonpersistent users restarted antiplatelet drugs later, leading to 89.3% overall antiplatelet drug users at 10 years after MI. Diabetes (hazard ratio [HR] 0.44; 0.32-0.60), hypertension (HR 0.77; 0.60-0.99), hypercholesterolaemia (HR 0.49; 0.39-0.62) and more recent MI diagnosis period (2003-2007: HR 0.69, 0.61-0.79; 2008-2010: HR 0.38, 0.19-0.77, compared to ≤ 2002 period) lowered the risk of antiplatelet nonpersistence, while vitamin K antagonist (VKA) comedication (HR 18.97; 16.91-21.28) increased this risk.



A large proportion of patients with a first MI still used antiplatelet drugs after 10 years. The frequent discontinuations during this time frame are expected to reduce the effectiveness of antiplatelet drugs as secondary prevention of cardiovascular diseases. Diabetes, hypertension, hypercholesterolaemia, VKA comedication and MI diagnosis period were determinants of antiplatelet nonpersistence.
Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.|Department of Pharmacology & Therapeutics, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, Indonesia.
Alfi
A
Yasmina
Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Anthonius
A
de Boer
Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, the Netherlands.
Vera H M
VH
Deneer
Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Patrick C
PC
Souverein
Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Olaf H
OH
Klungel
D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D012307:Risk Factors; D016903:Drug Monitoring
D010975:Platelet Aggregation Inhibitors
acute coronary syndrome; antiplatelet drugs; aspirin; clopidogrel; myocardial infarction
Eur J Prev Cardiol. 2013 Apr;20(2):218-28
22345684
Pharmacogenomics. 2010 Aug;11(8):1065-76
20712525
Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37
19287307
Circulation. 2010 Sep 7;122(10):1017-25
20733100
Eur Heart J. 2003 Jan;24(1):28-66
12559937
Eur Heart J. 2008 Dec;29(23):2909-45
19004841
Br J Pharmacol. 2015 Dec;172(24):6024-109
26650445
PLoS One. 2015 Apr 08;10(4):e0124314
25853836
Am J Cardiol. 2011 Jan 15;107(2):186-94
21211596
Eur Heart J. 2002 Dec;23(23):1809-40
12503543
Curr Med Res Opin. 2009 Sep;25(9):2327-34
19635046
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68
26464438
Eur J Clin Pharmacol. 2015 Feb;71(2):243-50
25529226
Arch Cardiovasc Dis. 2010 Jun-Jul;103(6-7):363-75
20800800
J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91
17174201
Eur Heart J. 2011 Oct;32(19):2376-86
21875855
Eur Heart J. 2007 Jul;28(13):1598-660
17569677
Eur Heart J. 2012 Oct;33(20):2569-619
22922416
N Engl J Med. 2007 Mar 8;356(10):1009-19
17296822
J Am Coll Cardiol. 2011 Mar 15;57(11):1251-63
21392639
N Engl J Med. 2007 Mar 8;356(10):998-1008
17296824
Br J Pharmacol. 2015 Dec;172(24):5744-869
26650439
J Cardiovasc Pharmacol Ther. 2015 Jul;20(4):378-86
25501499
J Hypertens. 2009 Jan;27(1):61-8
19145769
Eur Heart J. 2014 Nov 7;35(42):2950-9
25139896
Circulation. 2014 Apr 15;129(15):1577-85
24470482
Br J Clin Pharmacol. 2017 Mar;83(3):632-641
27662521
J Am Coll Cardiol. 2010 Jun 1;55(22):2427-34
20510210